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Because apoptosis of infected cells can limit virus
production and spread, some viruses have co-opted
prosurvival genes from the host. This includes the
Epstein-Barr virus (EBV) gene BHRF1, a homolog of
human Bcl-2 proteins that block apoptosis and are
associated with cancer. Computational design and
experimental optimization were used to generate a
novel protein called BINDI that binds BHRF1 with
picomolar affinity. BINDI recognizes the hydrophobic
cleft of BHRF1 in a manner similar to other Bcl-2
protein interactions but makes many additional con-
tacts to achieve exceptional affinity and specificity.
BINDI induces apoptosis in EBV-infected cancer
lines, and when delivered with an antibody-targeted
intracellular delivery carrier, BINDI suppressed
tumor growth and extended survival in a xenograft
disease model of EBV-positive human lymphoma.
High-specificity-designed proteins that selectively
kill target cells may provide an advantage over the
toxic compounds used in current generation anti-
body-drug conjugates.
INTRODUCTION
Following virus infection, cells may undergo apoptosis to prevent
further virus spread in the host. This has spurred viruses to
evolve counteracting mechanisms to prevent host cell death,
and during latent infection, these factors may contribute to the
development of cancer. In particular, there are multiple cancers
associated with Epstein-Barr virus (EBV), including Burkitt’s lym-
phoma (BL).1644 Cell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc.Apoptosis and cell survival are regulated by the homeostatic
balance of B cell lymphoma-2 (Bcl-2) family proteins (reviewed
in Martinou and Youle, 2011), which fall into three classes. The
‘‘executioners,’’ Bak and Bax, initiate apoptosis by increasing
mitochondrial outer membrane permeability and facilitating the
release of mitochondrial cytochrome c to the cytosol, which
activates downstream signaling. Six human prosurvival Bcl-2
proteins (Bcl-2, Bcl-XL, Bcl-B, Mcl-1, Bcl-w, and Bfl-1) inhibit
this process. Counterbalancing these are numerous proapopto-
tic BH3-only proteins, including Bim. These factors share an26
residue Bcl-2 homology 3 (BH3) motif, an amphipathic a-helical
element that binds a hydrophobic groove on the surface of the
canonical Bcl-2 fold. Cellular stresses activate proapoptotic
BH3-only proteins, which bind and inhibit prosurvival Bcl-2
members and directly interact with Bak and Bax to favor mito-
chondrial permeabilization. Conversely, prosurvival Bcl-2 pro-
teins dampen apoptotic triggers and enhance chemoresistance
by sequestering BH3-only proteins or directly inhibiting Bak and
Bax. Increased expression of prosurvival Bcl-2 proteins is a
common feature of many cancers.
Epstein-Barr virus encodes a prosurvival Bcl-2 homolog,
BHRF1, which prevents lymphocyte apoptosis during initial
infection by sequestering proapoptotic BH3-only proteins (espe-
cially Bim) and interacting directly with the executioner Bak
(Altmann and Hammerschmidt, 2005; Desbien et al., 2009; Hen-
derson et al., 1993; Kvansakul et al., 2010). Even though BHRF1
is under the control of an early lytic cycle promoter, low levels of
constitutive expression have been observed in some cases of
EBV-positive BL when the virus is latent, and it has been specu-
lated that BHRF1 may be a necessary viral factor for lymphoma-
genesis (Kelly et al., 2009; Leao et al., 2007; Watanabe et al.,
2010). However, although EBV is one of the earliest viruses to
be associated with human cancer, its molecular mechanism of
action remains unclear, in part because EBV-positive BLs can
have different expression profiles, suggesting that the molecular
etiology may not be universal (Kelly et al., 2009; Watanabe et al.,
2010).
In recent years, computation-based protein design has made
considerable progress, including the design of new hyperstable
structures (Koga et al., 2012) and the creation of functional sites
within existing proteins as scaffolds (Fleishman et al., 2011;
Procko et al., 2013). However, except in a few rare instances
(Correia et al., 2014; Lanci et al., 2012), the design of new struc-
tures that are also functional is a largely unmet challenge. Here,
we describe the creation of a picomolar inhibitor of BHRF1 by
designing a new protein de novo for optimum interactions. The
designed BHRF1 inhibitor triggers apoptosis in several EBV-
positive cancer lines, and when delivered with an antibody-tar-
geted carrier system, the inhibitor suppresses tumor progression
and extends survival in an animal model of human EBV-positive
lymphoma.
RESULTS
BHRF1-Binding Proteins Created by Grafting Bim-BH3
Side Chains to a Helical Scaffold
Prosurvival Bcl-2 proteins share a similar fold that resembles a
cupped hand, with a characteristic hydrophobic surface groove
that clasps one side of an amphipathic BH3 motif helix (Kvansa-
kul et al., 2010; Martinou and Youle, 2011). Rigidifying BH3 pep-
tides with hydrocarbon staples, disulfides, or lactam bridges on
the noninteractive back side of the helix can reduce the entropic
cost of a partially folded peptide acquiring a rigid helical confor-
mation upon binding and improves BH3 peptide affinity (Azzarito
et al., 2013). We reasoned that building a folded structure around
a BH3 peptide would similarly prestabilize the bound conforma-
tion but also provide additional interactions for increased affinity
and specificity. In previous work, interacting residues of the BH3
motif were grafted to the surface of aminimal structured peptide,
but after directed evolution, these folded peptides displayed only
moderate affinity and specificity and did not always bind to the
correct site on the target Bcl-2 protein (Chin and Schepartz,
2001; Gemperli et al., 2005). We instead sought to incorporate
the interacting residues of the BH3 motif onto an exposed sur-
face of a larger 3- or 4-helix bundle protein, which would thereby
allow additional contacts for increased affinity and specificity ex-
tending beyond the BH3 motif.
Two computational design strategies were used. The first was
a side-chain grafting approach onto existing natural proteins
(Figure S1A available online) (Correia et al., 2010; Ofek et al.,
2010). Three helical-bundle proteins were chosen as scaffolds
with different sizes and shapes for diversity: the small 3-helix
protein Z (PDB 1LP1 [Ho¨gbom et al., 2003]), a larger 3-helix
bundle derived from a bacterial ribosome recycling factor
(3LHP chain S [Correia et al., 2010]), and a 4-helix viral coat pro-
tein (3FBL [Goulet et al., 2009]). Beginning with the crystal struc-
ture of BHRF1 bound to a Bim-BH3 peptide (Kvansakul et al.,
2010), helical regions within the scaffolds were structurally
aligned to the Bim-BH3 helix. The scaffold positions correspond-
ing to Bim-BH3 residues, which interact with BHRF1, were then
mutated to the Bim-BH3 amino acids. Next, scaffold residues
surrounding the graft site were redesigned tominimize the calcu-
lated energy of the modeled bound complex (Kuhlman et al.,2003; Leaver-Fay et al., 2011). BHRF1 interface residues, which
normally reach over the backside of the Bim-BH3 helix, were
simultaneously repacked to alternative low-energy rotamers
compatible with the new designed interface. From six different
graft sites on the three scaffolds, three proteins (BbpG2.D,
BbpG3.D, and BbpG4.D; Data S1) were obtained with moderate
affinities for BHRF1 (apparent KDs of 60 to 80 nM as evaluated
using yeast surface display titrations; Figure 1A and Tables 1 and
S1). These affinities are weaker than the wild-type interaction
of Bim-BH3 with BHRF1, which has an apparent KD of 12 nM
(Table 1), probably reflecting nonoptimal backbone conforma-
tions and/or slightly unfavorable designed interactions outside
the core motif. To evaluate the importance of the additional de-
signed interactions outside the core motif, control designs were
produced in which Bim-BH3 binding residues were transplanted
to the scaffolds without redesign of the surrounding surface.
These control designs did not bind BHRF1 (Table S1), indicating
that computational design of novel interactions outside the core
motif was necessary.
Creating New Proteins for Optimized Interactions with
the BHRF1 Ligand-Binding Groove
Designed proteins from side-chain grafting are limited by the
assumed rigid backbone of the scaffold. To escape this
constraint, a second design strategy was used that builds pro-
tein structures de novo using proteins of known structure only
as topology guides (Correia et al., 2014). The Bim-BH3 helix
from the complex with BHRF1 was taken as a folding nucleus,
and helical bundle structures were assembled around it using
fragments from the PDB, followed by cycles of sequence design
and structure minimization. Ca-Ca atom-pair distances from the
topology guide constrained the assembling protein to within
3.0 A˚ root mean square deviation (rmsd) of the guide. Indepen-
dent runs of this stochastic design protocol gave an ensemble
of structural homologs, roughly centered on the guide scaffold
structure (Figure S1B). This protocol was previously applied to
the design of an immunogenic protein incorporating a viral
epitope, but in that case, the incorporated epitope provided all
necessary interactions with a target antibody (Correia et al.,
2014). Here, the incorporated Bim-BH3 motif provides only a
fraction of the interaction surface (40%), with potential for
many additional contacts across an expansive interface.
Each designed protein in the ensemble was docked to the
BHRF1 surface via alignment of the incorporated Bim-BH3motif,
and the surrounding interface residues were optimized as
described above. The designs were filtered both for stability of
the monomer and for interface quality. From thousands of com-
puter-assembled proteins, a small number of designs were
selected for further manual modifications, synthetic E. coli
codon-optimized genes were constructed, and those proteins
that were expressed and soluble in E. coli were tested by yeast
surface display for binding to BHRF1 (Table S2; yeast surface
display allows rapid measurement of approximate affinities and
is a powerful technology for later directed evolution). Two de-
signs with folds based on PDB 3LHP(S) were found to bind
BHRF1 with apparent KDs of 58–60 nM (BbpD04 and BbpD07;
Figure 1A, Table 1, and Data S1). These designs were ‘‘seeded’’
by a 15 residue fragment of the Bim-BH3motif of which nine sideCell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc. 1645
Figure 1. Computationally Designed Proteins Incorporating Elements of the Bim-BH3 Motif Bind BHRF1
(A) Computational models of individually tested designed proteins (orange) that bind BHRF1 (green). The crystal structure of BHRF1 bound to Bim-BH3 (blue)
is shown at left for comparison. BbpG designs are from side-chain grafting, and BbpD designs are de novo assembled proteins. Apparent affinities (mean ± SE,
n = 3–6) are from yeast display titrations. See also Figure S1 and Tables S1 and S2. An archive file of designed structures is provided in the Supplemental
Information online (Data S1).
(B) Seventy-four computationally designed proteins without human modifications (indexes 01 to 74 in Data S1) were included in a yeast display library. BbpD04
(index 00) was included as a positive control. The library was sorted for cells expressing surface protein (lane 1), for the 2%of cells with highest expression (lane 2),
and for cells showing binding signal after incubation with 100 nM (lane 3) or 400 nMBHRF1 (lane 4). The gene frequencies in the sorted population were divided by
their frequencies in the naive library to calculate a log2 enrichment ratio, plotted from 4 (i.e., depleted, red) to +4 (i.e., enriched, green). See also Table S3.
(C) Histogram of the mean rmsd between the ten lowest energy structures found in ab initio structure prediction calculations and the intended designed structure
for each of the sets of designs in (B). Designs with computed energy minima near the designed target conformation have a higher probability of binding BHRF1.
See also Figure S2.chains contacting the BHRF1 surface were kept fixed. Other res-
idues, primarily on the backside of the motif and buried in the
protein core, were designed to minimize the calculated potential
energy. The equivalent 3LHP(S) fixed backbone graft (design
BbpG1.D, Table S1) had numerous steric clashes between the
scaffold backbone and BHRF1 surface in the computational
model (described later) and failed to bind BHRF1.
In Silico Folding Probability Correlates with Binding
Activity
The success rate for designing functional proteins is low, and
design calculations are often followed by substantial human
intervention to choose and modify the designs prior to experi-
mental validation (Figure S2A). To investigate the factors distin-
guishing working from nonworking designs and to evaluate the1646 Cell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc.importance of human intervention, we characterized BHRF1
binding to a set of computational designs generated as
described for BbpD04 and BbpD07 but without any humanmod-
ifications. Seventy-four designs were displayed on yeast (Data
S1) and sorted with a single round of fluorescence-activated
cell sorting (FACS) for surface protein expression and BHRF1
binding. Deep sequencing revealed that five designs (indexes
00 to 04 in Data S1) were highly expressed and enriched after
sorting for BHRF1 interaction (Figures 1B and S2A–S2D and
Table S3); BHRF1 binding was confirmed on clonal yeast popu-
lations (Figure S2E). Standard computational metrics for assess-
ing interface quality or monomer stability did not distinguish the
working designs (Figures S2F–S2K). Instead, we found that
BHRF1 binding strongly correlated with the extent to which
the designed sequences folded to the designed structures in
Table 1. Affinities of Designed Proteins for Bcl-2 Family Members
Apparent Dissociation Constants from Yeast Surface Display Titrations (nM; mean ± SE, n = 3–6)
Protein BHRF1 Bcl-2 Bcl-w Mcl-1 Bfl-1 Bcl-XL Bcl-B
Bim-BH3 12 ± 4 2.02 ± 0.08 2.1 ± 0.1 0.6 ± 0.2 2.1 ± 0.3 3 ± 1 12.2 ± 0.1
BbpG2.D 60 ± 8 9 ± 1 >100 1.5 ± 0.3  106 ± 9 >100
BbpG3.D 70 ± 20 20 ± 2 4 ± 2 9 ± 2  31 ± 3 79 ± 8
BbpG4.D 81 ± 8 >100 35 ± 4 20 ± 3 >100 >100 80 ± 4
BbpD07 60 ± 10 76 ± 7  3.1 ± 0.3 >100  >100
BbpD04 58 ± 3   17 ± 7 >100  
BbpD04.1 8 ± 4 110 ± 20 14 ± 5 30 ± 10 >100 25 ± 1 
BbpD04.2 0.6 ± 0.2 33 ± 4 40 ± 10 26 ± 4 70 ± 20 31 ± 2 
BbpD04.3 0.54 ± 0.01 20 ± 2 34 ± 3 19 ± 1 32 ± 6 34 ± 7 
BINDI 0.9 ± 0.2 45 ± 7 60 ± 10 21.6 ± 0.8 >100 >100 
Accurate dissociation constants measured by BLI (nM; mean ± SD, n = 4–6)
Bim-BH3 7 ± 3 0.75 ± 0.09 20 ± 10 0.17 ± 0.02 0.61 ± 0.04 1.56 ± 0.09 7 ± 2
BINDI 0.22 ± 0.05 2,100 ± 100 870 ± 40 40 ± 10 2,600 ± 800 810 ± 80 >10,000
BINDI N62S 0.16 ± 0.08 30,000 ± 10,000 4,600 ± 400 230 ± 40 4,000 ± 2,000 8,000 ± 2,000 50,000 ± 10,000ab initio structure prediction calculations (Figures 1C and S2L).
Rather than a single calculated metric from a static representa-
tion of the structure, ab initio structure prediction generates
tens of thousands of conformations from stochastic folding sim-
ulations. Among the designs that bind BHRF1, the closer the pre-
dicted conformations are to the designed structure (i.e., lower
rmsd in Figure 1C), the lower their calculated energy and hence
the higher the probability of correctly folding. This observation
suggests that the primary shortcomings of inactive designs are
improper folding and designed state instability, rather than the
details of the designed protein-protein interface.
Enhanced BHRF1 Binding Affinity and Specificity
through Improved Electrostatic Complementarity
To illuminate BHRF1 biology, the designed protein must not only
bind with high affinity but do so specifically. Design BbpD04, a
de novo designed protein without sequence homologs identified
by BLAST (Altschul et al., 1997), bound BHRF1 with higher affin-
ity (apparent KD = 58 ± 3 nM) than all human prosurvival Bcl-2
proteins except Mcl-1 (Table 1) and was chosen for further opti-
mization. The computed electric field (Baker et al., 2001) experi-
enced by BbpD04 when bound to BHRF1 is markedly more
negative than when bound to Mcl-1 (Figures 2A and 2B). Nine
point substitutions were made to eight residues of BbpD04 to
specifically increase electrostatic complementarity for BHRF1.
Six decreased the KD(BHRF1)/KD(Mcl-1) ratio as predicted
(Table S4). The variant BbpD04.1 containing the best two point
mutations (E48R and E65R), together with a third compensatory
mutation (K31E) to preserve a putative stabilizing salt bridge,
bound BHRF1 with tighter affinity (Table 1).
Optimization of Affinity, Specificity, and Stability
Error-prone PCR mutagenesis of BbpD04.1, followed by FACS
for BHRF1 binding in the presence of unlabeled human Bcl-2
proteins to favor specificity, identified two mutations at the de-
signed interface (H104R, predicted to enhance electrostaticcomplementarity, and N62S, predicted to improve specificity
based on sequence-fitness landscape mapping described
below) and three mutations distal from the interface that might
alter protein stability. I21L slightly alters packing in the hydropho-
bic core, Q79L increases hydrophobic interactions buttressing
the second connecting loop, and L84Q forms a stabilizing
hydrogen bond to the loop backbone. The substitutions were
recombined in a combinatorial library, and FACS followed by
analysis of expression in E. coli identified a clone, BbpD04.2
(with four mutations, see Figure 2C), that was monodisperse
and monomeric by size exclusion chromatography (SEC) after
protein purification from E. coli (Figure S3). To enable site-
specific chemical coupling for later characterization, the single
internal cysteine of BbpD04.2 was removed by mutagenesis
(mutant C103A, called BbpD04.3; Table 1 and Figure S4).
To probe the sequence-fitness landscape of the designed pro-
tein, site-specific saturation mutagenesis was used to indepen-
dently diversify every codon of the BbpD04.3 gene to NNK (N is
any base, K is G or T), producing a library of (116 positions)3 (20
amino acids + stop codon) = 2,436 protein variants. The variants
were expressed on yeast, and the library was sorted by a single
round of FACS for BHRF1 affinity (Figure 2D) or affinity and spec-
ificity (unlabeled human Bcl-2 proteins were included as com-
petitors; Figure 2E). DNA was extracted from the naive and
postsorted yeast populations, and the BbpD04.3 coding region
was deep sequenced. The ratio of the frequencies of each pro-
tein variant in the presorted and postsorted population reports
on the effect of each substitution on affinity/specificity fitness.
The comprehensive BbpD04.3 affinity sequence-fitness land-
scape reveals the critical nature of the incorporated Bim-BH3
motif, withmost substitutions of interface residues depleted (Fig-
ure 2D). In addition, substitutions to proline, which can break
regular helical secondary structure, are depleted across the first,
second, and third helical spans of the designed helical bundle
fold. Substitutions to aspartate, a short and charged amino
acid, are depleted within the hydrophobic core as anticipated.Cell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc. 1647
Figure 2. Affinity Maturation of BbpD04
(A) Computational model of BHRF1 (light green ribbon) bound to design BbpD04 (transparent surface over a gray ribbon). The electrostatic potential from BHRF1
is shown on the BbpD04 surface (red,2 kT/e to blue, +2 kT/e; calculated using the Adaptive Poisson-Boltzmann Solver built in ROSETTA). Mutations E48R and
E65R (insets) decrease electrostatic repulsion in regions where the field from BHRF1 is negative.
(B) Same as in (A), with Mcl-1 in place of BHRF1. E48 and E65 are now in regions that border positive potential from Mcl-1. The Mcl-1,BbpD04 model was
generated by superposition of the BbpD04 binding site to Bim-BH3 bound to Mcl-1 in crystal structure 2PQK, followed by rotamer repacking and side-chain/
backbone minimization in ROSETTA. See also Table S4.
(C) The four additional mutations in BbpD04.2 (dark blue sticks) are shown on the computational model of BbpD04.1 (orange) bound to BHRF1 (green). Three
mutations are distant from the interface. See also Figures S3 and S4.
(legend continued on next page)
1648 Cell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc.
The BbpD04.3 affinity-specificity sequence-fitness landscape,
in which unlabeled Bcl-2 proteins were included as competitors
for BHRF1 binding, is similar (Figure 2E). Notably, several muta-
tions of Asn62, including N62S described in detail later, were
found to selectively increase BHRF1 specificity.
Bacterial expression of BbpD04.3 was very low, limiting the
quantity and purity that could be purified for biochemical applica-
tions. To improve expression, 29 BbpD04.3 point mutants with
positive enrichment ratios in either the affinity or affinity-speci-
ficity sequence-fitness landscapes were expressed in E. coli
and analyzed for increased soluble protein levels (Figure S5A).
All nine identified mutations—W3A/P, I13Q, F28L, M33R, F61Y,
W49E/Y, and M46E—reduce surface hydrophobicity, and, in
addition, W3A and W3P increase the helical propensity of the
initiating residue in the starting helix. These substitutions
perhaps reduce misfolding or aggregation, thereby reducing
clearance of the protein by the quality control machinery.
Because the mutations are generally surface exposed at distinct
sites on a long helical bundle, we reasoned that they could likely
be combined without negative interference (Figure S5B). A
BbpD04.3 variant with seven mutations (Figure S5C) had signif-
icantly increased bacterial expression and improved specificity
(Figure 2G and Table 1). This variant is named BHRF1-INhibiting
Design acting Intracellularly (BINDI). A summary of all mutations
introduced in the original design is provided in Figure 2I.
The increased affinity for BHRF1 following in vitro evolution cor-
relates with enhanced protein stability. Both BbpD04.3 and BINDI
undergocooperativeunfoldingathighconcentrations (>3M)of the
chemical denaturant guanidinium hydrochloridemeasured by cir-
cular dichroism (CD) spectroscopy (Figure 2H). However, the orig-
inal design,BbpD04,hasnearly linear lossofCDsignal overawide
concentration rangeofguanidiniumhydrochloride (Figure2H). The
absence of a cooperative melting transition is associated with
moltenglobules that lacka rigidcoreorsinglenativeconformation.
Although BbpD04, BbpD04.3, and BINDI have high thermosta-
bility and retain partly a-helical CD spectra at 95C, only evolved
BbpD04.3 and BINDI fully renature when the heated proteins are
cooled (Figures S5D–S5G). Further, the original BbpD04 design
is sensitive to rapid hydrolysis by proteases, which require
unfolded substrate backbone to access the enzyme active site,
whereas BINDI and BbpD04.3 are resistant (Figure S5H).
BINDI Binds BHRF1 with High Affinity and Specificity
Apparent dissociation constants by yeast surface display are
useful approximations but may be underestimated due to avidity(D) Sequence-fitness landscape. All single amino acid substitutions of BbpD04.3
signal for 400 pM biotinylated BHRF1 relative to surface expression were collecte
(depleted, orange) to +3.5 (enriched, blue). Stop codons, asterisk (*). The regio
structure and core residues (shaded gray) are indicated above. Substitutions to
helical residues) are boxed.
(E) Same as in (D), except the library was sorted for binding to 400 pM biotinyla
Substitutions of N62 are boxed.
(F) The modeled structure of BbpD04.3 is colored by sequence Shannon entro
sequence-fitness landscapes. A broken line boxes the incorporated Bim-BH3 m
(G) BbpD04.3 and its derivative BINDI were expressed as 6his-tagged proteins in
Coomassie-stained SDS-polyacrylamide electrophoretic gel. An arrowhead indic
(H) The fraction of protein folded in the presence of guanidinium hydrochloride b
(I) Summary of all mutations made to BbpD04 during affinity maturation.effects or ligand rebinding to a dense receptor surface or may
be overestimated if binding equilibrium is not reached. The
BINDI,BHRF1 interaction was therefore further characterized
by alternative methods. BINDI eluted as a higher-molecular-
weight complex by SEC when mixed with BHRF1 in solution,
whereas BINDI L54E with a knockout mutation in the designed
interface did not (Figures 3A and S3). Using bio-layer interferom-
etry (BLI) to measure the kinetic rate constants, BINDI,BHRF1
was found to form a very tight complex (KD 220 ± 50 pM) with
a slow dissociation rate (koff = [2.8 ± 0.9] 3 10
5 s1) (Figures
3B and 3D). BINDI has high specificity for BHRF1; the dissocia-
tion constants for human Bcl-2 family members are much
weaker. BINDI bound human Mcl-1 with KD 40 ± 10 nM
(180-fold increase compared to BHRF1), Bcl-2 with KD 2.1 ±
0.1 mM (10,000-fold increase), Bcl-w with KD 870 ± 40 nM
(4,000-fold increase), Bfl-1 with KD 2.6 ± 0.8 mM (12,000-fold
increase), Bcl-B with KD > 10 mM (>45,000-fold increase), and
Bcl-XL with KD 810 ± 80 nM (4,000-fold increase). The N62S
variant of BINDI was found to have even higher specificity
for BHRF1 versus Mcl-1, the closest competitor (Figure 3E).
Compared to the measured affinities of Bcl-2 proteins for Bim-
BH3 (Figure 3C) and to other published values (Caria et al.,
2012; Dutta et al., 2010, 2013; Gemperli et al., 2005; Kvansakul
et al., 2010; Lessene et al., 2013; Tse et al., 2008), the affinity
and specificity of BINDI for BHRF1 are considerably greater
than any previously described BHRF1 ligand and are similar to
or exceed that of any other protein, peptide, or drug designed
to specifically bind a Bcl-2 family protein.
The Crystal Structure of BINDI,BHRF1
The crystal structure of the BINDI,BHRF1 complex was deter-
mined at 2.05 A˚ resolution (Figure 4A and Table S5) and was
found to closely match the design model. The asymmetric unit
contains two nearly identical copies of BINDI-bound BHRF1;
the analysis presented here corresponds to one copy of the
complex (Figures S6A and S6B). The backbones of the crystal
structure and the original BbpD04,BHRF1 model align with a
Ca-CaRMSD of 1.06 A˚ (Figure 4B). The designed core and inter-
face regions were modeled accurately, whereas connecting
loops at the ends of the helical bundle deviate slightly from the
computational prediction (Figure 4C). Excluding flexible termini,
only two regions differ substantially from the model; BHRF1 loop
74-78 and BHRF1 loop 92-97 are located further away from the
interface in the crystal structure by 3 to 5 A˚ (Figures 4C, S6C, and
S6D). Our computational modeling assumed that the targetwere expressed in a yeast display library. The 1% of cells with highest binding
d by FACS. Plotted for each substitution is the log2 enrichment ratio from 3.5
n of the incorporated Bim-BH3 motif is boxed with a broken line. Secondary
aspartate (tend to be depleted for core residues) and to proline (depleted for
ted BHRF1 in the presence of 8 nM competitor Bcl-2 proteins for specificity.
py from 2.8 (highly conserved, dark blue) to 4.3 (variable, red) based on the
otif.
E. coli, precipitated from cleared lysate with NiNTA-agarose and analyzed on a
ates the expected MW at 15 kD. See also Figure S5.
ased on the change in CD signal at 222 nm. Mean ± SD from five scans.
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Figure 3. BINDI Binds BHRF1 with High Affinity and Specificity
(A) BINDI or knockout mutant BINDI L54E were mixed with BHRF1 and separated by SEC.
(B) Biotinylated BHRF1 was immobilized to a BLI sensor and the interaction with BINDI was measured at the indicated concentrations.
(C–E) BLI kinetic analysis of interactions between immobilized Bcl-2 proteins and soluble Bim-BH3 fused to the C terminus of maltose-binding protein (C), BINDI
(D), and BINDI N62S (E). Red labels on broken diagonal lines indicate the corresponding affinities/KD. Plotted are means ± SD from four to six experiments.BHRF1 backbone was rigid, and therefore, changes to the
target structure could not be anticipated. These regions
have been found to be flexible in BHRF1 and other Bcl-2
family members to accommodate the binding of different BH3
motif ligands (Fire et al., 2010; Kvansakul et al., 2010; Lee
et al., 2009).
BINDI incorporates the Bim-BH3 motif within a de novo de-
signed fold guided by the topology of PDB 3LHP chain S. As
noted earlier, the direct graft of Bim-BH3 interaction residues
to the equivalent site within the 3LHP(S) scaffold (design
BbpG1) failed to bind BHRF1, even after extensive design of
the surrounding interaction surface (design BbpG1.D; Table
S1). Although 3LHP(S) is structurally similar to BINDI, it is none-
theless a poor steric fit for the BHRF1-binding groove in this
design protocol. Aligning the graft site within 3LHP(S) to the
Bim-BH3 motif of BINDI in the BINDI,BHRF1 crystal structure
shows that the C-terminal helix of the grafted design comes
too close to the BHRF1 surface such that side chains would
clash (Figure 4D). An alignment of the crystal structure, design
model, and guide scaffold over the Bim-BH3 incorporation site
shows that the crystal structure is closer to the design model
than to the guide scaffold (Figure 4E). The rmsd between the
crystal and design models is 1.37 A˚ and is 1.86 A˚ between the
crystal and guide scaffold. Thus, the design process succeeded
in identifying a sequence that folds more closely to the designed
model than to the structure of the initial guide scaffold.
Compared to the native Bim-BH3 interaction, BINDI contacts
an additional 404 A˚2 on the surface of BHRF1 (Figures 4F–4K).
Residues from the Bim fragment that seeded design account
for just 587 A˚2 of the BINDI surface buried in the complex,1650 Cell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc.whereas designed residues account for 839 A˚2 (Figure 4H).
Only two residues at the periphery of the incorporated Bim-
BH3 motif changed during affinity maturation (the conservative
W49Y and F61Y substitutions), whereas all residues in the core
of the motif remained unchanged (Figures S6E–S6G). Intro-
ducing these twomutations into a Bim-BH3 peptide, or mutating
the Bim-BH3 peptide at all five positions within the BH3 region
that distinguish BbpD04 from specific BINDI, failed to achieve
the high affinity and specificity of BINDI (Figures S6H and S6I).
Likewise, excised peptides from BbpD04 and BINDI that could
be considered equivalent to a 26 residue BH3 motif, although
partially specific, again lack the affinity and specificity of BINDI
(Figures S6H and S6I). The extraordinary specificity of BINDI is
therefore accomplished through interactions across an expan-
sive interface, extending well beyond the central Bim-BH3 resi-
dues used to seed design.
BINDI Triggers Apoptosis Preferentially in EBV-Infected
Cells
We tested whether inhibition of BHRF1 via steric occlusion of the
BH3-binding groove with BINDI could induce mitochondrial
cytochrome c release in the EBV-positive BL cell line Ramos-
AW. Ramos-AW expresses BHRF1 at very low levels (Leao
et al., 2007) and therefore presents a challenging biological
target that likely expresses much higher levels of off-target
endogenous Bcl-2 family proteins. BINDI was applied to mito-
chondria isolated from both Ramos-AW and the EBV-negative
parental line Ramos (Andersson and Lindahl, 1976). BINDI
elicited greater cytochrome c release from Ramos-AW mito-
chondria (Figure 5A), indicating that an EBV-associated factor
Figure 4. The Crystal Structure of BINDI-Bound BHRF1
(A) Electron density at 2.0 s (blue mesh) in the region of the Bim-BH3 incorporation site. The crystallographic model of BINDI (orange) bound to BHRF1 (green) is
superimposed on the original starting computational model of BbpD04,BHRF1 (gray). Residues of BINDI and BHRF1 are labeled black and green, respectively,
and residues of BbpD04 prior to affinity maturation that differ are indicated in parentheses. See also Figure S6.
(B) The crystal structure of BINDI bound to BHRF1 superimposed on the original BbpD04,BHRF1 model.
(C) Agreement between the crystal structure and computational model is represented from low (thin blue tubing) to higher Ca-Ca RMSD (thick red tubing).
(D) Slice through the crystal structure of BINDI (orange ribbon) bound to BHRF1 (green ribbon with gray surface). The guiding scaffold 3LHP(S) (dark blue) is
aligned to BINDI at the Bim-BH3 incorporation site. A direct graft of the BH3motif into 3LHP(S) at this position causes clashes elsewhere with the BHRF1 surface.
(E) Aligned ribbon traces of BINDI from the BHRF1,BINDI crystal structure in orange; the computational model of BINDI in gray; and the crystal structure of the
guiding scaffold 3LHP(S) in dark blue. The three structures are aligned at the Bim-BH3 incorporation site on the middle helix in the back. The upper magnified
insets show the agreement between core residue conformations in the BINDI computational model versus the crystal structure. The lower magnified insets show
that the core residues of BINDI are distinct in both identity and position from those in the guiding scaffold. When aligned at the Bim-BH3 incorporation site, the
crystal structure is closer to the design model than the guiding scaffold.
(F) Crystal structure of BINDI (orange) bound to BHRF1 (green).
(G) The surface of BHRF1, in the same orientation as in (F), with the buried contact surface in BHRF1,BINDI colored blue.
(H) The surface of BINDI, rotated 180 compared to the orientation in (F), with the buried contact surface in BHRF1,BINDI colored. Buried residues whose
identities were taken from the incorporated Bim-BH3 fragment are magenta. Buried residues that were designed are blue.
(I) The crystal structure (PDB 2WH6) of Bim-BH3 (blue) bound to BHRF1 (green). Buried surface areas are calculated based on the 22 ordered residues of Bim built
into the electron density (a 26 residue Bim-BH3 peptide was crystallized with BHRF1 [Kvansakul et al., 2010]).
(J) The surface of BHRF1, in the same orientation as in (I), with the buried contact surface in BHRF1,Bim-BH3 colored blue.
(K) The surface of Bim-BH3, rotated 180 compared to the orientation in (I), with the buried contact surface in BHRF1,Bim-BH3 colored blue.is likely a BINDI target. Strikingly, the nonspecific Bim-BH3 pep-
tide had opposite behavior; mitochondria from EBV-negative
Ramos cells were more sensitive to Bim-BH3 treatment than
those from EBV-positive Ramos-AW cells. Indeed, EBV-positive
cell lines are widely reported as more resistant to nonselective
apoptotic stimuli (Ishii et al., 1995; Kvansakul et al., 2010; Leaoet al., 2007), making the enhanced activity of BINDI against
Ramos-AW cells all the more significant.
Although weaker than the picomolar affinity of BINDI for
BHRF1, the moderate affinity for Mcl-1 is likely the reason
BINDI still triggers apoptosis in the EBV-negative Ramos cell
line. It is possible that the enhanced toxicity of BINDI towardCell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc. 1651
Figure 5. BINDI Triggers Apoptosis in EBV-
Positive B Cell Lines
(A) Cytochrome c release from mitochondria
harvested from Ramos (EBV negative, gray) or
Ramos-AW cells (EBV positive, crimson) treated
with Bim-BH3 peptide (broken line) or BINDI
(solid line). Mean ± SD, n = 4, for (A)–(C). See also
Figure S7.
(B) Cytochrome c release from Ramos and
Ramos-AW mitochondria treated with 10 mM
BINDI or BINDI N62S.
(C) Mitochondria were harvested from EBV-
negative and -positive lines, and cytochrome c
release was measured after treatment with 10 mM
BINDI N62S.
(D) Cells were incubated with sublethal doses
(2 mM) of antennapedia peptide-fused BINDI or
3LHP(S). Diblock copolymer Pol300 was conju-
gated to the proteins for enhanced endosomal
escape. Cell viability (mean ± SD, n = 3) was
measured after 24 hr.Ramos-AW reflects increased Mcl-1-dependency in this line,
rather than expression of EBV BHRF1. To rule out this possibility,
we tested variant BINDI N62S with even greater specificity.
Asn62 of BINDI hydrogen bonds to the N terminus of BHRF1
helix a6, and serine at this position is predicted to similarly
interact at the interface (Figure S7B). BINDI N62S still binds
BHRF1 with tight affinity (KD 160 ± 80 pM) but with better spec-
ificity (Table 1 and Figure 3E); in particular, the affinity for Mcl-1 is
diminished 6-fold (KD 230 ± 40 nM). BINDI N62S has even
greater discrimination between Ramos and Ramos-AW cells
(Figure 5B). The enhanced activity of BINDI to initiate cyto-
chrome c release preferentially in EBV-positive cells is therefore
almost certainly due to BHRF1 inhibition.
Expression profiling of EBV-positive BLs has revealed distinct
subgroups (Kelly et al., 2013; Watanabe et al., 2010), and BHRF1
may not be important for cell survival in all cases. Including
Ramos and Ramos-AW, mitochondria were isolated from five
EBV-positive and three EBV-negative B cell lines. Bim-BH3 pep-
tide triggered cytochrome c release, whereas the inactive guide
scaffold 3LHP(S) had no effect (Figure S7C). Incubation with
BINDI N62S induced high cytochrome c release in three EBV-
positive lines (Figures 5B and 5C): BL lines Ramos-AW and
Daudi and B-prolymphocytic leukemia JVM-13. Two of the
EBV-positive lines had low levels of cytochrome c release similar
to EBV-negative cells, despite transcribing the BHRF1 gene (Fig-
ure S7C): BL line Raji and mantle cell lymphoma line JVM-2.
Hence, only some EBV-positive cancer lines appear to be
dependent on BHRF1 for survival.
BINDI was genetically fused with a C-terminal antennapedia
peptide for nonspecific cellular uptake and intracellular delivery
in vitro. BINDI-antennapedia applied to the growth medium at
4 mM selectively killed 40% of EBV-positive Ramos-AW cells
with no measurable death of EBV-negative Ramos cells (Fig-1652 Cell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc.ure S7D). Antennapedia-fused proteins
concentrate in endocytic organelles and
escape to the cytosol with low efficiency
(Duvall et al., 2010). To enhance endoso-mal escape, BINDI-antennapedia was conjugated via a terminal
cysteine to a diblock copolymer carrier, Pol300, comprising a
hydrophilic first block and a pH-responsive endosomolytic sec-
ond block (Convertine et al., 2010; Duvall et al., 2010; Manga-
niello et al., 2012). A lower 2 mM dose of BINDI-antennapedia
induced 60% cell death preferentially in Ramos-AW cells when
conjugated to the Pol300 polymeric carrier for enhanced cyto-
solic delivery (Figure 5D). Our data suggest that inhibition of
BHRF1 may effectively kill EBV-positive BL.
Treatment of EBV-Positive B Cell Lymphoma in a
Xenograft Mouse Model by Intracellular Delivery
of BINDI
Intracellular delivery of proteins in vivo is challenging, and there
are no current intracellular protein drugs available clinically. We
developed an antibody-micelle formulation to deliver BINDI to
intracellular targets in an EBV-positive human lymphoma dis-
ease model. BINDI was coupled via a C-terminal cysteine to a
diblock copolymer (Pol950); similar copolymers have been
shown to facilitate cytosolic release of fluorescent peptides
(Duvall et al., 2010) and have been coupled to antibodies for
cell targeting (Berguig et al., 2012). The copolymer’s hydrophilic
first block was composed of polyethylene glycol methacrylate
(MA) to improve safety and pharmacokinetic properties, pyridyl-
disulfide MA for cysteine conjugation to BINDI, and biotin-hy-
droxylethyl MA for coupling to streptavidin-antiCD19 (aCD19;
human monoclonal CAT-13.1E10-SA). The endosomolytic pH-
responsive second block was composed of diethylaminoethyl
MA and butyl MA. Copolymer:aCD19:BINDI forms micelles
that disassociate at endosomal pH to expose the membrane-
destabilizing segments (Figure 6A). CD19 is a rapidly internal-
izing surface antigen on B cells, and the aCD19-complex is
thought to be endocytosed followed by endosomal escape
Figure 6. Treatment of EBV-Positive B Cell Lymphoma Xenograft Tumors by Intracellular Delivery of BINDI In Vivo
(A) Schematic representation of the copolymer-based treatment. Pol950 has stabilizing (green) and endosomolytic (red) blocks and forms a micelle at physio-
logical pH. The stabilizing block couples to aCD19 and BINDI. Nudemice with subcutaneous Ramos-AW xenografts were treated on days 0, 3, and 6 with Pol950
(300 mg/kg): aCD19 (15 mg/kg): BINDI or 3LHP(S) (105 mg/kg). A maximum tolerated dose study determined that this level of BINDI was nontoxic. Mice were
injected 30 min prior to each treatment with CTX (35 mg/ml) and BTZ (0.5 mg/ml).
(B–E) Tumor growth is plotted for each individual mouse until day 11 when the first mice are euthanized. (B) PBS control treatment, black, n = 8; (C) chemo only,
gray, n = 9; (D) 3LHP(S)-copolymer treatment, green, n = 9; (E) BINDI-copolymer treatment, orange, n = 10.
(F) Kaplan-Meier survival plot. There is a significant increase in survival with treatment (log-rank test c2 = 46, p < 0.0001). See also Figure S7E.and protein drug release in the reducing environment of the
cytosol.
Subcutaneous Ramos-AW xenograft tumors were established
in nude BALB/c mice. The mice were treated intravenously on
days 0, 3, and 6 with antibody micelles coupled to the inactive
scaffold 3LHP(S) or to BINDI. Thirty minutes prior to each
treatment, cyclophosphamide (CTX) and bortezomib (BTZ)
were injected intraperitoneally at subtherapeutic doses to prime
cells for apoptosis (O’Connor et al., 2006). The treatments were
nontoxic with no substantial change in mouse body weight
(Figure S7E).
The intracellular delivery of BINDI to the B cell lymphoma
xenograft slowed tumor progression and prolonged survival.
Tumors grew rapidly in the untreated/PBS and chemo-only con-
trol groups (Figures 6B and 6C), withmean tumor sizes of 1,080 ±
500 mm3 and 680 ± 410 mm3, respectively, at day 11 when the
first mice were euthanized due to excessive tumor burden.
Both scaffold 3LHP(S) and BINDI treatment groups had reduced
tumor sizes due to the therapeutic effects of aCD19 coupled
to the micelle carrier, but BINDI substantially slowed tumor
growth compared to the scaffold control, especially during the
treatment cycle (140 ± 60 mm3 versus 330 ± 140 mm3 at day
11, unpaired t test p = 0.003, Figures 6D and 6E). Life span
was extended in the BINDI-treated mice compared to the scaf-
fold treatment (log-rank test p = 0.006), with median survival of15 days for PBS treatment, 16 days for chemo only, and
21 days for 3LHP(S) treatment, extending to 24 days following
BINDI treatment (Figure 6F). Future work is needed to determine
the fraction of proteins delivered with this new delivery carrier
that are internalized and directly engage intracellular targets.
Nonetheless, our data demonstrate that a de novo computation-
ally designed protein can reduce tumor growth in a preclinical
model.
DISCUSSION
By breaking free of the conformational constraints imposed by
repurposing pre-existing scaffolds and instead building a new
protein with structure tailored for the target surface, a remarkably
tight and specific binder of the EBV apoptosis regulator BHRF1
was designed. The elevated toxicity of the engineered BINDI
protein toward EBV-positive cancer lines supports the hypothe-
sis that BHRF1 is necessary for survival in at least some EBV-
associated cancers.
BINDI has a structure and amino acid sequence found after
computationally filtering thousands of potential designed confor-
mations for optimum interactions with BHRF1. The crystal struc-
ture is very close to the BINDI computational model, with the
orientations of helices differing from the guide scaffold in ways
critical for activity. The ability to custom tailor the backboneCell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc. 1653
conformation to the challenge at handwas critical to our success
in achieving very high affinity and specificity.
Protein structure and function are closely coupled, and our re-
sults demonstrate the importance of designing for stability in
addition to optimizing the binding interface. Designs with
BHRF1 binding activity had energy minima near the intended
target structure in ab initio structure calculations and directed
evolution of BbpD04 to enhance affinity introduced mutations
far from the interface that increased protein stability. Direct
in silico screening for a deep energyminimumaround the desired
conformation could considerably increase the success rate of
protein design efforts.
Finally, we demonstrate that BINDI can slow progression of
EBV-positive B cell lymphoma and prolong survival in a human
xenograft mouse model. The suppression of tumor growth dur-
ing treatment with BINDI provides proof-of-principle results
that a designer protein toxin can be antibody targeted and effec-
tive in vivo. Further optimization of dosing, targeting, and the
carrier may all increase therapeutic efficacy, and incorporation
of catalytic activity in the designed protein, for example site-spe-
cific proteolysis, would boost potency. Designer toxins with high
potency and specificity could provide the basis for a next gener-
ation of antibody-drug conjugates for the treatment of cancer.
EXPERIMENTAL PROCEDURES
Protein Design and Purification
Proteins were designed using the ROSETTA software suite, and designed
protein geneswere synthesized by oligo assembly or by commercial suppliers.
Designed proteins (cloned into pET29b [Novagen]) were purified with C-termi-
nal 6His-tags from E. coli BL21(DE3) by NiNTA-affinity chromatography
(QIAGEN) and SEC (GE Healthcare). Target Bcl-2 proteins had C-terminal
avi-6His tags and were similarly purified from E. coli, followed by enzymatic
biotinylation using BirA (Avidity). Biotinylated proteins were further purified
by additional rounds of NiNTA-affinity chromatography and SEC. All purified
proteins were concentrated with ultrafiltration centrifugal devices (Sartorius),
snap frozen in liquid nitrogen and stored at 80C.
Yeast Surface Display
Design optimization was by yeast surface display. Designed protein genes
were cloned into plasmid pETCON (Fleishman et al., 2011) and expressed
as fusions with N-terminal Aga2p for surface attachment and a C-terminal
myc-tag in the EBY100 strain. Surface expression was detected with
anti-myc-FITC (Immunology Consultants Laboratory), whereas binding to
biotinylated Bcl-2 proteins after coincubation for 1–4 hr at 22C in phos-
phate-buffered saline was detected with phycoerythrin-streptavidin (Invitro-
gen). Yeast were sorted with a BD Influx cell sorter. Gene sequences were
diversified either by assembly of degenerate oligos, by overlapping PCR for
generating the site-specific saturation mutagenesis library (Procko et al.,
2013), or by error-prone PCR with an average error rate of 1.3 aa substitutions
per clone using GeneMorph II Random Mutagenesis (Agilent Technologies).
Crystallization and Structure Determination
Untagged BINDI and C-terminal 6his-BHRF1 were copurified from E. coli
lysate via NiNTA-affinity chromatography and SEC. Crystals of the complex
were grown by vapor diffusion after mixing 1:1 drops of protein with reservoir
(8%–12% PEG8000, 100 mM Tris-Cl [pH 8.5], 200 mM MgCl2) and were cry-
opreserved with 18%–20% glycerol in mother liquid prior to flash freezing.
Data sets were collected with a Rigaku MicroMax-007HF rotating anode
home source and at beam line BL 5.0.2 at the Advanced Light Source at
Lawrence Berkeley National Laboratory. The structure was determined by
molecular replacement with chain A of PDB 2WH6 and a computational model
of BINDI.1654 Cell 157, 1644–1656, June 19, 2014 ª2014 Elsevier Inc.Apoptosis Assays
Cytochrome c release was measured by ELISA (Life Technologies) from iso-
lated mitochondria after treating with the indicated peptides/proteins for
0.5 hr at room temperature. For cell viability studies, protein and protein-poly-
mer conjugates were incubated with Ramos or Ramos-AW cells for 24 hr, and
viability was measured using a CellTiter 96 Aqueous One Solution Cell Prolif-
eration Assay,MTS (Promega). For these studies, Bim-BH3 peptide (sequence
Ac-MRPEIWIAQELRRIGDEFNAC-ON) was synthesized by solid phase syn-
thesis and purified.
Diblock Copolymers
Pol950 and Pol300 diblock copolymers were synthesized by reversible addi-
tion-fragmentation chain transfer. Pol300 is a 25,000 Da diblock copolymer
composed of 95% polyethylene glycol MA (300 Da) and 5% pyridyl disulfide
MA in the first block and 60% diethylaminoethyl MA and 40% butyl MA in the
second block. Pol950 is a 44,000 Da diblock copolymer composed of 80%
polyethylene glycol MA (950 Da), 10%pyridyl disulfideMA, and 10%biotin-hy-
droxyethyl MA in the first block and 60% diethylaminoethyl MA and 40% butyl
MA in the second block. The full synthesis, development, and pharmaceutical
properties of the carriers will be published in a separate manuscript.
Xenograft Disease Model
BALB/c nu/nu mice (6 to 8 weeks old) were housed under protocols approved
by the FHCRC Institutional Animal Care and Use Committee. Ramos-AW cells
(107 cells/200 ml) were injected in the right flank (day 6), and tumors grew for
6 days to a volume of 50 mm3. Mice with similar-sized tumors were sorted
randomly into treatment groups (n = 8 to 10). On days 0, 3, and 6, mice were in-
jected intraperitoneally with CTX (35 mg/kg) and BTZ (0.5 mg/kg). After 0.5 hr,
mice were injected via tail vein with conjugates at a dose of 15 mg/kg (aCD19;
cloneCAT-13.1E10 produced in themonoclonal production facility at FHCRC),
300 mg/kg (Pol950), and 105 mg/kg (BINDI or 3LHP). Body weight was moni-
tored for toxicity, and tumor sizes were measured while blinded to treatment
groups. Mice were euthanized when tumors reached a volume of 1,250 mm3.
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